We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+6.38%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.96B
AUM Growth
+$853M
(+12%)
Cap. Flow
+$1.08B
Cap. Flow
% of AUM
13.6%
Top 10 Holdings %
Top 10 Hldgs %
33.59%
Holding
163
New
28
Increased
23
Reduced
24
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prelude Therapeutics
PRLD
|
+$440M |
| 2 |
PMV Pharmaceuticals
PMVP
|
+$270M |
| 3 |
AFIB
Acutus Medical Inc
AFIB
|
+$166M |
| 4 |
Adicet Bio
ACET
|
+$95.1M |
| 5 |
Theravance Biopharma
TBPH
|
+$68.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$119M |
| 2 |
Cigna
CI
|
+$82.5M |
| 3 |
Natera
NTRA
|
+$64.2M |
| 4 |
Alector
ALEC
|
+$52.6M |
| 5 |
Glaukos
GKOS
|
+$46.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.96% |
| 2 | Financials | 0.63% |
| 3 | Technology | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Corvus Pharmaceuticals
CRVS
$1.1B
| $27.1M | 0.34% |
6,767,584
| – | – |
|
77
Arcturus Therapeutics
ARCT
$161M
| $26.5M | 0.33% |
618,586
+379,400
| +159% | +$18.8M |
|
78
Standard BioTools
LAB
$321M
| $26.4M | 0.33% |
3,553,703
+646,603
| +22% | +$4.46M |
|
|
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
| $24.7M | 0.31% |
53,154
-23,246
| -30% | -$11.7M |
|
80
NextCure
NXTC
$22.9M
| $23.9M | 0.3% |
225,918
| – | – |
|
81
Amgen
AMGN
$212B
| $23.3M | 0.29% |
91,500
| – | – |
|
|
NVO
82
Novo Nordisk
NVO
$228B
| $22.9M | 0.29% |
660,000
| – | – |
|
|
NMTR
83
DELISTED
9 Meters Biopharma
NMTR
| $20.5M | 0.26% |
1,285,838
| – | – |
|
|
CTIC
84
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $20.5M | 0.26% |
9,520,600
| – | – |
|
85
Alcon
ALC
$34B
| $19.9M | 0.25% |
351,380
| – | – |
|
|
ISEE
86
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $19.2M | 0.24% |
3,411,806
+161,806
| +5% | +$772K |
|
|
OSH
87
DELISTED
Oak Street Health, Inc.
OSH
| $17.9M | 0.22% |
+334,400
| New | +$15M |
|
|
TRIL
88
DELISTED
Trillium Therapeutics Inc.
TRIL
| $17.8M | 0.22% |
1,252,600
+41,600
| +3% | +$415K |
|
89
Heron Therapeutics
HRTX
$93.7M
| $17.7M | 0.22% |
1,191,846
+531,426
| +80% | +$8.29M |
|
|
FLXN
90
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $17.5M | 0.22% |
1,684,000
| – | – |
|
91
Teva Pharmaceuticals
TEVA
$39.4B
| $17.4M | 0.22% |
1,935,200
| – | – |
|
92
Guardant Health
GH
$19B
| $17.2M | 0.22% |
+154,300
| New | +$14.1M |
|
|
PAND
93
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
| $17M | 0.21% |
+1,480,940
| New | +$25.3M |
|
94
Forte Biosciences
FBRX
$1.57B
| $16.5M | 0.21% |
13,619
-24,394
| -64% | -$16.2M |
|
95
Syndax Pharmaceuticals
SNDX
$1.68B
| $16.1M | 0.2% |
1,094,100
| – | – |
|
96
Zymeworks
ZYME
$1.63B
| $15.9M | 0.2% |
341,102
-241,200
| -41% | -$8.28M |
|
|
SRRA
97
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $15.8M | 0.2% |
1,477,320
| – | – |
|
98
Relay Therapeutics
RLAY
$3.95B
| $14.9M | 0.19% |
+350,000
| New | +$13.3M |
|
99
BiomX
PHGE
$1.96M
| $14.7M | 0.18% |
12,176
| – | – |
|
|
ALXN
100
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $14.3M | 0.18% |
125,000
+25,000
| +25% | +$2.7M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q3 2020 Portfolio in Review
As of Q3 2020, OrbiMed held 163 positions worth $7.96B, up 12% from $7.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed deployed $1.08B of net new capital in Q3 2020, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was Prelude Therapeutics: 15,594,877 shares worth $470M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $119M trimmed.
- OrbiMed's largest Q3 2020 buy was Prelude Therapeutics: 15,594,877 shares worth $470M.
- OrbiMed added most to Adicet Bio in Q3 2020, an estimated $95.1M increase.
- OrbiMed's biggest Q3 2020 reduction was Ascendis Pharma A/S, cutting an estimated $119M.
- OrbiMed fully exited Cigna in Q3 2020, selling an estimated $82.5M.
- OrbiMed's ten largest holdings make up 34% of its $7.96B portfolio in Q3 2020.
- OrbiMed opened 28 new positions and closed 20 in Q3 2020.
- OrbiMed's portfolio value rose 12% quarter-over-quarter to $7.96B.
Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.